TY - JOUR
T1 - Biochemical properties and regulation of cathepsin K activity
AU - Lecaille, Fabien
AU - Brömme, Dieter
AU - Lalmanach, Gilles
N1 - Funding Information:
Some important references have been omitted because of space limitations. We are indebted to all those who have worked with us and all the scientists who have contributed to the research reviewed here. The English text was edited by Dr Owen Parkes (Romagné, France). This work was partly supported by the Canadian Research Chair award and a National Institutes of Health grant (D.B.). Previous works in the laboratory (INSERM U618) were founded by Biotechnocentre (France), EU (5th European Community Framework Programme), l'ARC (Association pour la Recherche sur le Cancer, France) and Vaincre les Maladies Lysosomales (France) (G.L.).
PY - 2008/2
Y1 - 2008/2
N2 - Cysteine cathepsins (11 in humans) are mostly located in the acidic compartments of cells. They have been known for decades to be involved in intracellular protein degradation as housekeeping proteases. However, the discovery of new cathepsins, including cathepsins K, V and F, has provided strong evidence that they also participate in specific biological events. This review focuses on the current knowledge of cathepsin K, the major bone cysteine protease, which is a drug target of clinical interest. Nevertheless, we will not discuss recent developments in cathepsin K inhibitor design since they have been extensively detailed elsewhere. We will cover features of cathepsin K structure, cellular and tissue distribution, substrate specificity, and regulation (pH, propeptide, glycosaminoglycans, oxidants), and its putative roles in physiological or pathophysiological processes. Finally, we will review the kinetic data of its inhibition by natural endogenous inhibitors (stefin B, cystatin C, H- and L-kininogens).
AB - Cysteine cathepsins (11 in humans) are mostly located in the acidic compartments of cells. They have been known for decades to be involved in intracellular protein degradation as housekeeping proteases. However, the discovery of new cathepsins, including cathepsins K, V and F, has provided strong evidence that they also participate in specific biological events. This review focuses on the current knowledge of cathepsin K, the major bone cysteine protease, which is a drug target of clinical interest. Nevertheless, we will not discuss recent developments in cathepsin K inhibitor design since they have been extensively detailed elsewhere. We will cover features of cathepsin K structure, cellular and tissue distribution, substrate specificity, and regulation (pH, propeptide, glycosaminoglycans, oxidants), and its putative roles in physiological or pathophysiological processes. Finally, we will review the kinetic data of its inhibition by natural endogenous inhibitors (stefin B, cystatin C, H- and L-kininogens).
KW - Cystatin
KW - Cysteine cathepsin
KW - Cysteine protease
KW - Kininogen
KW - Osteoporosis
KW - Stefin
KW - Substrate specificity
UR - http://www.scopus.com/inward/record.url?scp=38849159247&partnerID=8YFLogxK
U2 - 10.1016/j.biochi.2007.08.011
DO - 10.1016/j.biochi.2007.08.011
M3 - Article
C2 - 17935853
AN - SCOPUS:38849159247
SN - 0300-9084
VL - 90
SP - 208
EP - 226
JO - Biochimie
JF - Biochimie
IS - 2
ER -